Renin–angiotensin system blockade reduces cardiovascular events in nonheart failure, stable patients with prior coronary intervention

BACKGROUNDThe effects of renin–angiotensin system (RAS) blockade on the clinical outcome in patients with stable coronary artery disease (SCAD) are conflicting. We evaluated the long-term effects of RAS blockers (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker) on the clinical outcomes in patients with SCAD without heart failure (HF) who underwent percutaneous coronary intervention (PCI) with drug-eluting stent using a large-scale, multicenter, prospective cohort registry. METHODSA total of 5722 patients with SCAD were enrolled and divided into two groups according to the use of RAS blockers after PCIRAS blocker group included 4070 patients and no RAS blocker group included 1652 patients. Exclusion criteria were left ventricular ejection fraction less than 50% and the history of HF or myocardial infarction. A major adverse cardiovascular event (MACE) was defined as a composite of cardiovascular death, nonfatal myocardial infarction, and stroke. RESULTSDuring a median follow-up of 29.7 months, RAS blockers were associated with a significant reduction in the risk of MACE [adjusted hazard ratio (HR)0.781; 95% confidence interval (CI)0.626–0.975; P=0.015] and all-cause death (adjusted HR0.788; 95% CI0.627–0.990; P=0.041) but did not affect the risk of coronary revascularization. In the propensity score matched cohort, overall findings were consistent (MACEadjusted HR0.679; 95% CI0.514–0.897; P=0.006; all-cause deathadjusted HR0.723; 95% CI0.548–0.954; P=0.022), and the benefit of RAS blockade was maintained in all predefined subgroups. CONCLUSIONThis study demonstrated that RAS blockers were effective preventive therapies for reducing long-term cardiovascular events in patients with SCAD without HF who underwent PCI.